| Followers | 76 |
| Posts | 12053 |
| Boards Moderated | 3 |
| Alias Born | 06/03/2008 |
Wednesday, April 09, 2025 3:48:43 PM
This is insanity! They said nothing EVER about the drug, or can be shown that they did anything with it, in 4 years, so that means "we can conclude" it's valuable? This a wish, not a logical take based on company data or any company statements!
You haven't addressed what I asked. I am trying to show the huge holes in your due diligence and how the losses are your fault. You avoided most of my questions. You have shown NOTHING in my challenge to show any updates or discussing to this drug in the years ENZC owned it. The answer is ZERO correct? Then say so!
Do you agree that ENZC gave zero updates with progress or even concrete plans to go ahead with testing/phase 1 testing, and showed zero evidence that they did any more testing of any type. Yes or No? Simple question! If no, then post links to the statements they made showing progress or what data ENZC released.
We haven't even gotten started here. If you want me to show you what you missed, you need to address ALL of my questions or points, and be prepared to discuss them further. If you don't want to see or learn from your mistakes, and yes they are YOUR mistakes, just say so, and we'll end the discussion!
Exxe Group Advances Platform Strategy and Share Structure Reduction Following Strategic Meetings • AXXA • Mar 11, 2026 1:03 PM
DRCR Pushes Forward With Implementation of 2026 Business Plan • DRCR • Mar 11, 2026 12:26 PM
Record Gold Prices Reshape Opportunities for Emerging Producers • LFLR • Mar 11, 2026 9:00 AM
C2 Blockchain Reports 803 Million DOG (Bitcoin) Holdings Following Strategic Accumulation of Bitcoin-Native Digital Assets • CBLO • Mar 10, 2026 8:00 AM
RENI Completes Due Diligence on Target Acquisition; Confirms Strong Asset Base and Operational Performance • RENI • Mar 5, 2026 10:15 AM
BlackStar Engages in Talks with U.S. Senate Banking Committee Team Covering the Digital Asset Market Clarity Act • BEGI • Mar 4, 2026 4:47 PM
